NCT03826992View on ClinicalTrials.gov

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Leukemia
Interventions
DRUG

Vyxeos

Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.

DRUG

Venetoclax

"Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days"

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER